GGrantIndex
← Leaderboards

Ren Xu

University Of Kentucky

$8,252,231
Attributed
$8,439,603
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,439,603 · 6

By mechanism

R01$7,101,992 · 4
P20$962,866 · 1
R21$374,745 · 1

Top collaborators

Most similar at University Of Kentucky

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Breast Neoplasm

Research focus

Malignant Breast NeoplasmNeoplasm MetastasisMultidisciplinaryPathway InteractionsPositioning AttributeMolecularTumor ProgressionTissuesBreast Cancer CellMalignant NeoplasmsCancer CellBreast Cancer ProgressionKnockout MiceBreastRegulationCoculture TechniquesLoss Of FunctionIn VivoInsightBiologyBreast Epithelial CellsExperimental StudyMediatingCells

Grant awards (26)

Roles of mRNA Transfer in Cancer Cell-Platelet Communication$393,513
R01 · FY2025 · CA · contact PI
Roles of Hsp47 in Breast Cancer Progression$363,375
R01 · FY2025 · CA · contact PI
The PLOD2/succinate axis in cancer cell plasticity and stemness$353,981
R01 · FY2025 · CA · contact PI
Roles of mRNA Transfer in Cancer Cell-Platelet Communication$378,223
R01 · FY2024 · CA · contact PI
The PLOD2/succinate axis in cancer cell plasticity and stemness$347,390
R01 · FY2024 · CA · contact PI
Roles of Hsp47 in Breast Cancer Progression$345,206
R01 · FY2024 · CA · contact PI
Roles of mRNA Transfer in Cancer Cell-Platelet Communication$401,867
R01 · FY2023 · CA · contact PI
The PLOD2/succinate axis in cancer cell plasticity and stemness$365,673
R01 · FY2023 · CA · contact PI
Roles of Hsp47 in Breast Cancer Progression$356,108
R01 · FY2023 · CA · contact PI
Roles of Hsp47 in Breast Cancer Progression$363,375
R01 · FY2022 · CA · contact PI
Roles of RORalpha in breast cancer development and progression$226,782
R01 · FY2022 · CA · contact PI
Roles of Hsp47 in breast cancer progression$344,269
R01 · FY2021 · CA · contact PI
Roles of RORalpha in breast cancer development and progression$112,859
R01 · FY2021 · CA · contact PI
Roles of Hsp47 in breast cancer progression$344,269
R01 · FY2020 · CA · contact PI
Roles of RORalpha in breast cancer development and progression$344,269
R01 · FY2020 · CA · contact PI
Roles of RORalpha in breast cancer development and progression$333,940
R01 · FY2019 · CA · contact PI
Roles of Hsp47 in breast cancer progression$333,940
R01 · FY2019 · CA · contact PI
Project 3: Role of RORa in Breast Cancer Metastasis$320,956
P20 · FY2019 · GM · contact PI
Roles of RORalpha in breast cancer development and progression$360,146
R01 · FY2018 · CA · contact PI
Roles of Hsp47 in breast cancer progression$344,269
R01 · FY2018 · CA · contact PI
Project 3: Role of RORa in Breast Cancer Metastasis$320,954
P20 · FY2018 · GM · contact PI
Roles of Hsp47 in breast cancer progression$344,269
R01 · FY2017 · CA · contact PI
Roles of RORalpha in breast cancer development and progression$344,269
R01 · FY2017 · CA · contact PI
Project 3: Role of RORa in Breast Cancer Metastasis$320,956
P20 · FY2017 · GM · contact PI
Systemic delivery of miR-29 for basal-like breast cancer treatment$163,669
R21 · FY2017 · CA · contact PI
Systemic delivery of miR-29 for basal-like breast cancer treatment$211,076
R21 · FY2016 · CA · contact PI